LIVIVO - Search results -

Search results

Result 1 - 10 of total 186

Search options

Article ; Online: Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations.

Perkmann, Thomas / Springer, David N / Mucher, Patrick / Wolzt, Michael / Weseslindtner, Lukas / Haslacher, Helmuth

Journal of clinical virology plus

2023 Volume 3, Issue 3, Page(s) 100157

Abstract: Objective: To investigate whether SARS-CoV-2 omicron breakthrough infection in individuals after three doses of wildtype-based BNT162b2 increases antibody levels measured by a commercially available wildtype-based immunoassay.: Methods: 16 of 21 ... ...

Abstract	Objective: To investigate whether SARS-CoV-2 omicron breakthrough infection in individuals after three doses of wildtype-based BNT162b2 increases antibody levels measured by a commercially available wildtype-based immunoassay. Methods: 16 of 21 individuals in a BNT162b2 vaccination cohort (recruited 129 [129-135] days after dose 3) experienced a breakthrough infection (BTI) between March and September 2022. Antibodies to the receptor binding domain (RBP) of the spike protein (Anti-S) were quantified using the wildtype-based Elecsys SARS-CoV-2 S assay (Roche). Antibody responses of triple vaccinated BTI cases were compared to triple vaccinated individuals without breakthrough infection and to 16 matched individuals after primary omicron infection. Results: In the 16 individuals with primary Omicron infection, the anti-S assay returned only very low results (2.25 [0.61-5.80] U/mL). However, in individuals with BTI, Anti-S levels rose from 7,135 [5,870-17,470] U/mL to 21,705 (7,750-46,137.5) U/mL. At the same time, Anti-S concentrations decreased from 9,120 [7,480-13,480] U/mL to 3,830 (2,390-4,220) U/mL in those 5 of 21 vaccinated only. Conclusions: Our data suggest that breakthrough infection with omicron can efficiently boost wild-type antibodies in individuals vaccinated with wild-type BNT162b2.
Language	English
Publishing date	2023-06-28
Publishing country	England
Document type	Journal Article
ISSN	2667-0380
ISSN (online)	2667-0380
DOI	10.1016/j.jcvp.2023.100157
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection.

Perkmann, Thomas / Perkmann-Nagele, Nicole / Koller, Thomas / Mucher, Patrick / Radakovics, Astrid / Wolzt, Michael / Wagner, Oswald F / Binder, Christoph J / Haslacher, Helmuth

European journal of clinical investigation

2021 Volume 51, Issue 11, Page(s) e13632

Abstract: Background: There is preliminary evidence that individuals with previous SARS-CoV-2 infections exhibit a more pronounced antibody response. However, these assumptions have not yet been supported by data obtained through various CE-marked tests. This ... ...

Abstract	Background: There is preliminary evidence that individuals with previous SARS-CoV-2 infections exhibit a more pronounced antibody response. However, these assumptions have not yet been supported by data obtained through various CE-marked tests. This study aimed to close this gap. Methods: Sixty-nine seronegatives and 12 individuals post-SARS-CoV-2 infection (tested by CE-labelled Roche NC immunoassay or PCR-confirmed assay) were included 21 ± 1 days after receiving the first dose of the Pfizer/BioNTech BNT162b2 vaccine. Antibody response to viral spike protein (S) was assessed by CE-labelled Roche S and DiaSorin S1/S2 assays and by a surrogate virus neutralization test (sVNT). Results: After a single dose of BNT162b2, individuals after natural SARS-CoV-2 infection presented with markedly higher anti-S levels than naïve individuals (Roche S: 9078.5 BAU/mL [5267.0-24 298.5] vs 79.6 [24.7-142.3]; and DiaSorin S1/S2: 1465.0 AU/mL [631.0-5365.0] vs 63.7 [47.8-87.5]) and showed all the maximum observed inhibition activity in the sVNT (98%), without overlaps between groups. There was a trend for higher responses in those with a more distant infection, although not statistically significant. The relative antibody increase after dose 2 was significantly higher among naïve individuals (25-fold), but antibody levels remained below that of seropositives. Conclusions: Compared with naïve individuals, seropositives after natural SARS-CoV-2 infection presented with a substantially higher antibody response already after dose 1 of BNT162b2, as measured by two CE-marked in vitro diagnostic tests and a sVNT. These results should stimulate discussion and research on whether individuals after previous SARS-CoV-2 infection would benefit from a two-part vaccination schedule or whether these currently much-needed second doses could be saved.
MeSH term(s)	Adult ; Age Factors ; Antibodies, Viral/immunology ; Antibody Formation/immunology ; BNT162 Vaccine ; COVID-19/immunology ; COVID-19/prevention & control ; COVID-19 Serological Testing ; COVID-19 Vaccines/therapeutic use ; Coronavirus Nucleocapsid Proteins/immunology ; Female ; Humans ; Male ; Middle Aged ; Phosphoproteins/immunology ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/immunology
Chemical Substances	Antibodies, Viral ; COVID-19 Vaccines ; Coronavirus Nucleocapsid Proteins ; Phosphoproteins ; Spike Glycoprotein, Coronavirus ; nucleocapsid phosphoprotein, SARS-CoV-2 ; spike protein, SARS-CoV-2 ; BNT162 Vaccine (N38TVC63NU)
Language	English
Publishing date	2021-08-01
Publishing country	England
Document type	Journal Article ; Observational Study
ZDB-ID	186196-7
ISSN	1365-2362 ; 0014-2972 ; 0960-135X
ISSN (online)	1365-2362
ISSN	0014-2972 ; 0960-135X
DOI	10.1111/eci.13632
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 677: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction.

Taleb, Adam / Willeit, Peter / Amir, Shahzada / Perkmann, Thomas / Kozma, Maria Ozsvar / Watzenböck, Martin L / Binder, Christoph J / Witztum, Joseph L / Tsimikas, Sotirios

Journal of lipid research

2023 Volume 64, Issue 6, Page(s) 100391

Abstract: Immunoglobulin M (IgM) autoantibodies to oxidation-specific epitopes (OSEs) can be present at birth and protect against atherosclerosis in experimental models. This study sought to determine whether high titers of IgM titers to OSE (IgM OSE) are ... ...

Abstract	Immunoglobulin M (IgM) autoantibodies to oxidation-specific epitopes (OSEs) can be present at birth and protect against atherosclerosis in experimental models. This study sought to determine whether high titers of IgM titers to OSE (IgM OSE) are associated with a lower risk of acute myocardial infarction (AMI) in humans. IgM to malondialdehyde (MDA)-LDL, phosphocholine-modified BSA, IgM apolipoprotein B100-immune complexes, and a peptide mimotope of MDA were measured within 24 h of first AMI in 4,559 patients and 4,617 age- and sex-matched controls in the Pakistan Risk of Myocardial Infarction Study. Multivariate-adjusted logistic regression was used to estimate odds ratio (OR) and 95% confidence interval for AMI. All four IgM OSEs were lower in AMI versus controls (P < 0.001 for all). Males, smokers and individuals with hypertension and diabetes had lower levels of all four IgM OSE than unaffected individuals (P < 0.001 for all). Compared to the lowest quintile, the highest quintiles of IgM MDA-LDL, phosphocholine-modified BSA, IgM apolipoprotein B100-immune complexes, and MDA mimotope P1 had a lower OR of AMI: OR (95% confidence interval) of 0.67 (0.58-0.77), 0.64 (0.56-0.73), 0.70 (0.61-0.80) and 0.72 (0.62-0.82) (P < 0.001 for all), respectively. Upon the addition of IgM OSE to conventional risk factors, the C-statistic improved by 0.0062 (0.0028-0.0095) and net reclassification by 15.5% (11.4-19.6). These findings demonstrate that IgM OSE provides clinically meaningful information and supports the hypothesis that higher levels of IgM OSE may be protective against AMI.
MeSH term(s)	Male ; Infant, Newborn ; Humans ; Epitopes ; Antigen-Antibody Complex ; Phosphorylcholine ; Myocardial Infarction ; Autoantibodies ; Immunoglobulin M ; Apolipoproteins ; Lipoproteins, LDL
Chemical Substances	Epitopes ; Antigen-Antibody Complex ; Phosphorylcholine (107-73-3) ; Autoantibodies ; Immunoglobulin M ; Apolipoproteins ; Lipoproteins, LDL
Language	English
Publishing date	2023-05-19
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	80154-9
ISSN	1539-7262 ; 0022-2275
ISSN (online)	1539-7262
ISSN	0022-2275
DOI	10.1016/j.jlr.2023.100391
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 175: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comparison of five Anti-SARS-CoV-2 antibody assays across three doses of BNT162b2 reveals insufficient standardization of SARS-CoV-2 serology.

Perkmann, Thomas / Mucher, Patrick / Ösze, Darlene / Müller, Antonia / Perkmann-Nagele, Nicole / Koller, Thomas / Radakovics, Astrid / Flieder, Ines / Repl, Manuela / Marculescu, Rodrig / Wolzt, Michael / Wagner, Oswald F / Binder, Christoph J / Haslacher, Helmuth

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

2022 Volume 158, Page(s) 105345

Abstract: Objectives: To investigate the comparability of WHO standard referenced commercial SARS-CoV-2 antibody tests over three doses of BNT162b2 vaccine and up to 14 months.: Methods: 114 subjects (without previous SARS-CoV-2 infection or immunosuppressive ... ...

Abstract	Objectives: To investigate the comparability of WHO standard referenced commercial SARS-CoV-2 antibody tests over three doses of BNT162b2 vaccine and up to 14 months. Methods: 114 subjects (without previous SARS-CoV-2 infection or immunosuppressive medication) vaccinated with three doses of BNT162b2 were included in this study. Antibody levels were quantified 3 weeks after the first dose, 5-6 weeks and 7 months after the second dose, and 4-5 weeks and 4 months after the third dose using the Roche Elecsys SARS-CoV-2 S, the Abbott SARS-CoV-2 IgG II Quant, the DiaSorin LIAISON SARS-CoV-2 TrimericS IgG, the GenScript cPASS sVNT and the TECO sVNT assays. Results: For each time point analyzed, systematic differences are evident between the results in BAU/mL of the three antibody binding assays. The assay ratios change in a time-dependent manner even beyond administering the third dose (Roche measuring 9 and 3 times higher than Abbott and DiaSorin, respectively). However, changes decrease in magnitude with increasing time intervals from the first dose. IgG-based assays show better agreement across them than with Roche (overall correlations: Abbott x DiaSorin: ρ = 0.94 vs. Abbott x Roche: ρ=0.89, p < 0.0001; DiaSorin x Roche: ρ = 0.87, p < 0.0001), but results are not interchangeable. The sVNTs suggest an underestimation of antibody levels by Roche and slight overestimation by both IgG assays after the first vaccine dose. Conclusions: Standardization of SARS-CoV-2 antibody binding assays still needs to be improved to allow reliable use of variable assay systems for longitudinal analyses.
MeSH term(s)	Humans ; SARS-CoV-2 ; COVID-19 ; BNT162 Vaccine ; Antibodies, Viral ; Immunoglobulin G
Chemical Substances	BNT162 Vaccine ; Antibodies, Viral ; Immunoglobulin G
Language	English
Publishing date	2022-11-25
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1446080-4
ISSN	1873-5967 ; 1386-6532
ISSN (online)	1873-5967
ISSN	1386-6532
DOI	10.1016/j.jcv.2022.105345
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3790: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study.

Perkmann, Thomas / Mucher, Patrick / Perkmann-Nagele, Nicole / Radakovics, Astrid / Repl, Manuela / Koller, Thomas / Schmetterer, Klaus G / Bigenzahn, Johannes W / Leitner, Florentina / Jordakieva, Galateja / Wagner, Oswald F / Binder, Christoph J / Haslacher, Helmuth

Microbiology spectrum

2022 Volume 10, Issue 1, Page(s) e0140221

Abstract: Various commercial anti-Spike SARS-CoV-2 antibody tests are used for studies and in clinical settings after vaccination. An international standard for SARS-CoV-2 antibodies has been established to achieve comparability of such tests, allowing conversions ...

Abstract	Various commercial anti-Spike SARS-CoV-2 antibody tests are used for studies and in clinical settings after vaccination. An international standard for SARS-CoV-2 antibodies has been established to achieve comparability of such tests, allowing conversions to BAU/mL. This study aimed to investigate the comparability of antibody tests regarding the timing of blood collection after vaccination. For this prospective observational study, antibody levels of 50 participants with homologous AZD1222 vaccination were evaluated at 3 and 11 weeks after the first dose and 3 weeks after the second dose using two commercial anti-Spike binding antibody assays (Roche and Abbott) and a surrogate neutralization assay. The correlation between Roche and Abbott changed significantly depending on the time point studied. Although Abbott provided values three times higher than Roche 3 weeks after the first dose, the values for Roche were twice as high as for Abbott 11 weeks after the first dose and 5 to 6 times higher at 3 weeks after the second dose. The comparability of quantitative anti-Spike SARS-CoV-2 antibody tests was highly dependent on the timing of blood collection after vaccination. Therefore, standardization of the timing of blood collection might be necessary for the comparability of different quantitative SARS-COV-2 antibody assays.
MeSH term(s)	Adult ; Antibodies, Viral/blood ; COVID-19/diagnosis ; COVID-19/immunology ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/immunology ; Humans ; Middle Aged ; Prospective Studies ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology ; Time Factors ; Vaccination/standards ; Vaccination/trends
Chemical Substances	Antibodies, Viral ; COVID-19 Vaccines ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
Language	English
Publishing date	2022-02-23
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Observational Study
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/spectrum.01402-21
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.

Bonelli, Michael Markus / Mrak, Daniel / Perkmann, Thomas / Haslacher, Helmuth / Aletaha, Daniel

Annals of the rheumatic diseases

2021 Volume 80, Issue 10, Page(s) 1355–1356

MeSH term(s)	Antibodies, Viral/blood ; Antibodies, Viral/immunology ; Antirheumatic Agents/therapeutic use ; COVID-19/prevention & control ; COVID-19 Vaccines/immunology ; Humans ; Immunity, Cellular/drug effects ; Immunity, Cellular/immunology ; Immunity, Humoral/drug effects ; Immunity, Humoral/immunology ; Immunocompromised Host/immunology ; Immunogenicity, Vaccine/drug effects ; Immunogenicity, Vaccine/immunology ; Rheumatic Diseases/drug therapy ; Rheumatic Diseases/immunology ; Rituximab/therapeutic use ; SARS-CoV-2
Chemical Substances	Antibodies, Viral ; Antirheumatic Agents ; COVID-19 Vaccines ; Rituximab (4F4X42SYQ6) ; BNT162 vaccine (N38TVC63NU)
Language	English
Publishing date	2021-05-06
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	7090-7
ISSN	1468-2060 ; 0003-4967
ISSN (online)	1468-2060
ISSN	0003-4967
DOI	10.1136/annrheumdis-2021-220408
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 167: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Performance Evaluation of the Fully Automated NeuMoDx RT-PCR Platform for the Quantification of CMV and EBV DNA in EDTA Plasma: Implications for Clinical Management and Establishment of a Conversion Formula.

Herdina, Anna Nele / Ratzinger, Franz / Breuer, Monika / Schellnegger, Julia / Chen, Rui Qiang / Watkins-Riedel, Thomas / Perkmann-Nagele, Nicole / Strassl, Robert

Microbiology spectrum

2022 , Page(s) e0215722

Abstract: The NeuMoDx96 platform is a fully automated real-time PCR (RT-PCR) system. To provide continued testing quality with the introduction of new assays, the primary aim of this study was to evaluate the analytical and clinical performance of the NeuMoDx ... ...

Abstract	The NeuMoDx96 platform is a fully automated real-time PCR (RT-PCR) system. To provide continued testing quality with the introduction of new assays, the primary aim of this study was to evaluate the analytical and clinical performance of the NeuMoDx platform for the detection and quantification of CMV and EBV DNA in EDTA plasma. As no conversion from log
Language	English
Publishing date	2022-11-07
Publishing country	United States
Document type	Journal Article
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/spectrum.02157-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results.

Perkmann, Thomas / Koller, Thomas / Perkmann-Nagele, Nicole / Klausberger, Miriam / Duerkop, Mark / Holzer, Barbara / Hartmann, Boris / Mucher, Patrick / Radakovics, Astrid / Ozsvar-Kozma, Maria / Wagner, Oswald F / Binder, Christoph J / Haslacher, Helmuth

Microbiology spectrum

2021 Volume 9, Issue 1, Page(s) e0021821

MeSH term(s)	Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; COVID-19/diagnosis ; COVID-19/immunology ; COVID-19 Serological Testing ; Humans ; Neutralization Tests/methods ; Nucleocapsid/immunology ; SARS-CoV-2/immunology ; SARS-CoV-2/isolation & purification ; Spike Glycoprotein, Coronavirus/immunology
Chemical Substances	Antibodies, Neutralizing ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2
Language	English
Publishing date	2021-06-16
Publishing country	United States
Document type	Letter
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/Spectrum.00218-21
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Growth Differentiation Factor 15 Is Associated with Platelet Reactivity in Patients with Acute Coronary Syndrome.

Mutschlechner, David / Tscharre, Maximilian / Wadowski, Patricia P / Pultar, Joseph / Weikert, Constantin / Lee, Silvia / Eichelberger, Beate / Panzer, Simon / Perkmann, Thomas / Gremmel, Thomas

Journal of clinical medicine

2023 Volume 12, Issue 4

Abstract: Bleeding events in patients with acute coronary syndrome (ACS) are a risk factor for adverse outcomes, including mortality. We investigated the association of growth differentiation factor (GDF)-15, an established predictor of bleeding complications, ... ...

Abstract	Bleeding events in patients with acute coronary syndrome (ACS) are a risk factor for adverse outcomes, including mortality. We investigated the association of growth differentiation factor (GDF)-15, an established predictor of bleeding complications, with on-treatment platelet reactivity in ACS patients undergoing coronary stenting receiving prasugrel or ticagrelor. Platelet aggregation was measured by multiple electrode aggregometry (MEA) in response to adenosine diphosphate (ADP), arachidonic acid (AA), thrombin receptor-activating peptide (TRAP, a protease-activated receptor-1 (PAR-1) agonist), AYPGKF (a PAR-4 agonist) and collagen (COL). GDF-15 levels were measured using a commercially available assay. GDF-15 correlated inversely with MEA ADP (r = -0.202,
Language	English
Publishing date	2023-02-17
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm12041627
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays.

Perkmann, Thomas / Perkmann-Nagele, Nicole / Koller, Thomas / Mucher, Patrick / Radakovics, Astrid / Marculescu, Rodrig / Wolzt, Michael / Wagner, Oswald F / Binder, Christoph J / Haslacher, Helmuth

Microbiology spectrum

2021 Volume 9, Issue 1, Page(s) e0024721

Abstract: Reliable quantification of the antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly relevant, e.g., for identifying possible vaccine failure and estimating the time of protection. Therefore, we evaluated five ... ...

Abstract	Reliable quantification of the antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly relevant, e.g., for identifying possible vaccine failure and estimating the time of protection. Therefore, we evaluated five different anti-SARS-CoV-2 antibody assays regarding the quantification of anti-spike (S) antibodies. Sera from 69 SARS-CoV-2-naive individuals 21 ± 1 days after vaccination with a single dose of BNT162b2 (Pfizer/BioNTech) were tested using the following quantitative assays: Roche S total antibody, DiaSorin trimeric spike IgG, DiaSorin S1/S2 IgG, Abbott II IgG, and Serion/Virion IgG. Results were further compared to the percent inhibition calculated from a surrogate virus neutralization test (sVNT). Individual values were distributed over several orders of magnitude for all assays. Although the assays were in good overall agreement (ρ = 0.80 to 0.94), Passing-Bablok regression revealed systematic constant and proportional differences, which could not be eliminated by converting the results to binding antibody units (BAU) per milliliter, as suggested by the manufacturers. Seven (10%) individuals had negative sVNT results (i.e., <30% inhibition). These samples were identified by most assays and yielded significantly lower binding antibody levels. Although all assays showed good correlation, they were not interchangeable, even when converted to BAU per milliliter using the WHO international standard for SARS-CoV-2 immunoglobulin. This highlights the need for further standardization of SARS-CoV-2 serology.
MeSH term(s)	Adult ; Antibodies, Neutralizing ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; BNT162 Vaccine ; COVID-19/immunology ; COVID-19 Vaccines/immunology ; Female ; Humans ; Immunoglobulin G/blood ; Male ; Middle Aged ; Neutralization Tests ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology ; Vaccination
Chemical Substances	Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Immunoglobulin G ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; BNT162 Vaccine (N38TVC63NU)
Language	English
Publishing date	2021-06-30
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/Spectrum.00247-21
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito